Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as Advanced Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic change called the KRAS G12C mutation. The study is testing a treatment involving two medications: Adagrasib, which is taken as a tablet, and Pembrolizumab, which is given through an infusion into a vein. The purpose of the study is to evaluate how effective and safe these treatments are for patients with this type of lung cancer.

The study is divided into two phases. In the first phase, some patients will receive Adagrasib alone, while others will receive a combination of Adagrasib and Pembrolizumab. In the second phase, the study will compare the combination of Adagrasib and Pembrolizumab against Pembrolizumab alone. This will help researchers understand which treatment works better for patients with this specific mutation in their lung cancer.

Participants in the study will receive their assigned treatment and will be monitored over time to see how their cancer responds. The study will also look at the safety of the treatments by checking for any side effects. The goal is to find the best treatment option for patients with Advanced Non-Small Cell Lung Cancer with the KRAS G12C mutation.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's objectives and procedures. The patient will be required to provide consent to participate in the study.

  2. Step 2

    Initial assessment

    The patient will undergo an initial assessment to confirm eligibility. This includes a diagnosis of advanced non-small cell lung cancer with a specific genetic mutation known as KRAS G12C.

  3. Step 3

    Treatment phase 2

    In phase 2, the patient will receive adagrasib as a monotherapy or in combination with pembrolizumab. Adagrasib is administered orally in the form of a film-coated tablet. Pembrolizumab is given intravenously as a solution for infusion.

  4. Step 4

    Treatment phase 3

    In phase 3, the patient will receive a combination of adagrasib and pembrolizumab, or pembrolizumab alone. The treatment aims to compare the effectiveness of the combination therapy against pembrolizumab alone.

  5. Step 5

    Monitoring and evaluation

    Throughout the trial, the patient's response to the treatment will be monitored. This includes regular assessments to measure the size of the tumor and any changes in the patient's condition.

  6. Step 6

    Safety and side effects

    The safety of the treatment will be evaluated by monitoring any side effects or adverse reactions. The patient will be asked to report any symptoms experienced during the trial.

  7. Step 7

    Completion of the trial

    Upon completion of the trial, the patient will undergo a final assessment to evaluate the overall effectiveness of the treatment. The results will contribute to the understanding of the treatment's impact on advanced non-small cell lung cancer.

Who can join the trial?

11 criteria

  • Patients must have a confirmed diagnosis of **unresectable** or **metastatic** **Non-Small Cell Lung Cancer (NSCLC)**. "Unresectable" means the cancer cannot be removed with surgery, and "metastatic" means the cancer has spread to other parts of the body.
  • The cancer must have a specific genetic change called the **KRAS G12C mutation**.
  • For Phase 2, patients can have any level of **PD-L1 TPS**. PD-L1 TPS is a measure of a protein that can affect how the immune system responds to cancer.
  • For Phase 3, patients must have a **PD-L1 TPS** of 50% or higher.
  • For Phase 3, patients must have cancer that can be measured or evaluated using a standard method called **RECIST version 1.1**.
  • For Phase 3, patients must have one of the following conditions regarding the brain:
    • No evidence of cancer spread to the brain.
    • Untreated cancer spread to the brain that does not need immediate treatment.
    • Previously treated cancer spread to the brain that does not need immediate treatment.
    • Patients must be adults, as the study includes age ranges 3 and 4, which typically refer to adults.
    • Both **male** and **female** patients can participate.
    • The study does not include vulnerable populations, meaning it is not designed for groups that might need special protection.

Who cannot join the trial?

6 criteria

  • Patients who do not have Advanced Non-Small Cell Lung Cancer cannot participate. This is a type of lung cancer that is more advanced.
  • Patients without the KRAS G12C mutation are excluded. This is a specific change in the cancer's genetic material.
  • Patients who are not candidates for first-line treatment are excluded. First-line treatment is the initial treatment given for a disease.
  • Patients with a PD-L1 TPS less than 50% are excluded. PD-L1 TPS is a measure of a protein that can affect how the immune system responds to cancer.
  • Patients with unresectable cancer are included. Unresectable means the cancer cannot be removed with surgery.
  • Patients with locally advanced or metastatic cancer are included. Locally advanced means the cancer has spread to nearby areas, and metastatic means it has spread to other parts of the body.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Adagrasib

    is a medication being studied for its potential to treat advanced non-small cell lung cancer (NSCLC) in patients with a specific genetic mutation known as KRAS G12C. It is being tested both on its own and in combination with another medication to see how effective and safe it is for patients who are receiving their first treatment for this type of cancer.

  • Pembrolizumab

    is a medication that helps the immune system fight cancer. It is being used in combination with adagrasib in this trial to see if the two medications together can better treat advanced non-small cell lung cancer in patients with the KRAS G12C mutation. The trial aims to determine if this combination is more effective than using pembrolizumab alone.

What is already known about the treatment

Adagrasib – Adagrasib is administered orally and is currently being studied in clinical trials for its effectiveness in treating advanced non-small cell lung cancer (NSCLC) with a specific KRAS G12C mutation. It is being evaluated both as a standalone treatment and in combination with Pembrolizumab. The medication works by specifically targeting and inhibiting the KRAS G12C mutation, which is a common driver of cancer cell growth in this type of lung cancer. Adagrasib is classified as a targeted cancer therapy, focusing on molecular changes that are specific to cancer cells.

Investigated diseases

Advanced Non-Small Cell Lung Cancer – This is a type of lung cancer that begins in the cells lining the lungs and is characterized by its non-small cell nature, which means the cancer cells are larger than those found in small cell lung cancer. It is considered advanced when it has spread beyond the lungs to other parts of the body. The disease progresses as the cancer cells grow and divide uncontrollably, forming tumors that can interfere with normal lung function. Over time, these tumors may invade nearby tissues and organs, leading to further complications. The progression can vary significantly among individuals, depending on factors like genetic mutations and overall health.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2023-508922-83-00Protocol code849-007Estimated enrolment821 patientsSponsorMirati Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).